ADAM15 Inhibitor Program
Ocular Neovascular Disease (e.g., wet AMD) & Solid Tumors (e.g., Prostate/Breast Cancer)
Pre-clinicalActive
Key Facts
Indication
Ocular Neovascular Disease (e.g., wet AMD) & Solid Tumors (e.g., Prostate/Breast Cancer)
Phase
Pre-clinical
Status
Active
Company
About Vasgen
Vasgen is a private, pre-clinical stage biotech developing novel antibody-based inhibitors targeting ADAM proteases for ocular and cancer indications. Its core asset is the AbIMP® platform, designed to overcome historical challenges in inhibiting metzincin proteases. The company is actively seeking investment and partnerships to advance its lead pre-clinical program, with key validation points including proof-of-concept data and grant funding.
View full company profile